重大事件
即時報告
8-K
2026-06-08
Neurogene Inc. 提交 Form 8-K 文件，申報日期為 2026 年 6 月 8 日。 本次申報主要涉及兩項項目：第 7.01 項（監管 FD 披露）及第 9.01 項（財務報表與附件）。
AI 繁中摘要
Neurogene Inc. 提交 Form 8-K 文件，申報日期為 2026 年 6 月 8 日。📄 本次申報主要涉及兩項項目：第 7.01 項（監管 FD 披露）及第 9.01 項（財務報表與附件）。
公司隨附兩份附件：EX-99.1 為新聞稿，內容關於 PRX embolden 劑量完成（Dosing Completion）；EX-99.2 則為企業簡報（Corporate Presentation）。雖然本次 8-K 未有提供具體財務數字，但從標題推測，Neurogene 可能在 PRX（一項基因治療或罕見疾病藥物）的臨床試驗中達到重要里程碑——完成患者給藥。此消息對生物科技投資者而言屬正面催化劑，尤其是若後續數據有望支持療效或安全性。
管理層尚未在本次申報中發表明確展望，但企業簡報通常會更新研發管線進度、關鍵臨床試驗時間表及資金狀況。投資者應密切留意後續公布的完整簡報內容，以評估 PRX 項目的商業化潛力及公司短期現金消耗情況。
對股價潛在影響：完成劑量給藥往往被視為研發進展信號，可能帶動短期股價波動；但需注意此為監管 FD 披露，不構成正式業績公告，建議參考隨後的正式臨床數據發佈。🧬
展開英文正文
EDGAR Filing Documents for 0001404644-26-000044 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001404644-26-000044 Filing Date 2026-06-08 Accepted 2026-06-08 07:32:53 Documents 47 Period of Report 2026-06-08 Items Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K ngne-20260608.htm iXBRL 8-K 28428 2 EX-99.1 ngne_prxemboldendosingcomp.htm EX-99.1 18525 3 EX-99.2 a202606_ngnecorporatepre.htm EX-99.2 42465 7 a202606_ngnecorporatepre001.jpg GRAPHIC 114982 8 a202606_ngnecorporatepre002.jpg GRAPHIC 271881 9 a202606_ngnecorporatepre003.jpg GRAPHIC 114443 10 a202606_ngnecorporatepre004.jpg GRAPHIC 176657 11 a202606_ngnecorporatepre005.jpg GRAPHIC 33173 12 a202606_ngnecorporatepre006.jpg GRAPHIC 148261 13 a202606_ngnecorporatepre007.jpg GRAPHIC 129373 14 a202606_ngnecorporatepre008.jpg GRAPHIC 99892 15 a202606_ngnecorporatepre009.jpg GRAPHIC 101913 16 a202606_ngnecorporatepre010.jpg GRAPHIC 32376 17 a202606_ngnecorporatepre011.jpg GRAPHIC 86193 18 a202606_ngnecorporatepre012.jpg GRAPHIC 98511 19 a202606_ngnecorporatepre013.jpg GRAPHIC 101042 20 a202606_ngnecorporatepre014.jpg GRAPHIC 128756 21 a202606_ngnecorporatepre015.jpg GRAPHIC 76220 22 a202606_ngnecorporatepre016.jpg GRAPHIC 120849 23 a202606_ngnecorporatepre017.jpg GRAPHIC 132417 24 a202606_ngnecorporatepre018.jpg GRAPHIC 100801 25 a202606_ngnecorporatepre019.jpg GRAPHIC 45225 26 a202606_ngnecorporatepre020.jpg GRAPHIC 138514 27 a202606_ngnecorporatepre021.jpg GRAPHIC 149760 28 a202606_ngnecorporatepre022.jpg GRAPHIC 123639 29 a202606_ngnecorporatepre023.jpg GRAPHIC 44001 30 a202606_ngnecorporatepre024.jpg GRAPHIC 100991 31 a202606_ngnecorporatepre025.jpg GRAPHIC 131219 32 a202606_ngnecorporatepre026.jpg GRAPHIC 132630 33 a202606_ngnecorporatepre027.jpg GRAPHIC 46892 34 a202606_ngnecorporatepre028.jpg GRAPHIC 107659 35 a202606_ngnecorporatepre029.jpg GRAPHIC 101965 36 a202606_ngnecorporatepre030.jpg GRAPHIC 83752 37 a202606_ngnecorporatepre031.jpg GRAPHIC 73206 38 a202606_ngnecorporatepre032.jpg GRAPHIC 53363 39 a202606_ngnecorporatepre033.jpg GRAPHIC 73716 40 image_0.jpg GRAPHIC 3474 Complete submission text file 0001404644-26-000044.txt 5023943 Data Files Seq Description Document Type Size 4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20260608.xsd EX-101.SCH 1788 5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20260608_lab.xml EX-101.LAB 22548 6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20260608_pre.xml EX-101.PRE 13050 50 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20260608_htm.xml XML 2802 Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020 Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings) EIN.: 980542593 | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 261071038 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)